Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• J&J’s nipocalimab trial for FNAIT set to begin phase 3

  A Phase 3 clinical trial aiming to assess the safety and efficacy of nipocalimab in pregnancies at risk of FNAIT is set to begin soon.

• Rallybio’s novel therapy successfully prevents FNAIT in mice

  In a recent study, Rallybio’s new therapy, RLYB212, successfully prevented fetal and neonatal alloimmune thrombocytopenia in mice.

• Characteristics of prenatal intracranial hemorrhage due to FNAIT

  The distinct patterns of perinatal intracranial hemorrhage (pIH), a feared FNAIT complication, were detailed in a recent study.

• ITP may lead to thrombocytopenia in newborns

  Like FNAIT, maternal immune thrombocytopenic purpura (ITP) can lead to thrombocytopenia in newborns, according to a recent study.

• Europe greenlights experimental FNAIT therapy for further trials

  A Phase 2 clinical trial for an experimental treatment for FNAIT was recently approved by the European Medicines Agency.

• Donor characteristics may affect quality of FNAIT transfusions

  A recent study showed donor characteristics can affect the quantity of platelets obtained for FNAIT platelet transfusions.

• Potential therapeutic alternative for FNAIT shows early promise

  Researchers have successfully synthesized an antibody against the CD36 platelet antigen, which has potential therapeutic implications for FNAIT.

• Study: No significant difference between FNAIT diagnostic tests

  A recent study found no significant differences in accuracy between methods for detecting detecting anti-HPA antibodies responsible for FNAIT.

• FcRn inhibitors as a potential treatment for FNAIT

  Neonatal fragment crystallizable receptor (FcRn) inhibitors could significantly decrease complications associated with FNAIT, recent studies show.

• Drug to prevent FNAIT shows promise in early-stage trial

  Results from the phase 1 clinical trial of RLYB212, an experimental therapy intended for FNAIT prevention, were recently published.